LU91556I2 - Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB - Google Patents

Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB

Info

Publication number
LU91556I2
LU91556I2 LU91556C LU91556C LU91556I2 LU 91556 I2 LU91556 I2 LU 91556I2 LU 91556 C LU91556 C LU 91556C LU 91556 C LU91556 C LU 91556C LU 91556 I2 LU91556 I2 LU 91556I2
Authority
LU
Luxembourg
Prior art keywords
human
chain
region
reconstituted
receptor
Prior art date
Application number
LU91556C
Other languages
English (en)
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26370596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91556(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP3095476A external-priority patent/JPH05236966A/ja
Priority claimed from JP4032084A external-priority patent/JPH05227970A/ja
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of LU91556I2 publication Critical patent/LU91556I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LU91556C 1991-04-25 2009-04-24 Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB LU91556I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3095476A JPH05236966A (ja) 1991-04-25 1991-04-25 ヒトインターロイキン−６レセプターに対するマウスモノクローナル抗体の可変領域をコードするｄｎａ
JP4032084A JPH05227970A (ja) 1992-02-19 1992-02-19 ヒトインターロイキン−６受容体に対する再構成ヒト抗体
PCT/JP1992/000544 WO1992019759A1 (fr) 1991-04-25 1992-04-24 Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine

Publications (1)

Publication Number Publication Date
LU91556I2 true LU91556I2 (fr) 2009-06-24

Family

ID=26370596

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91556C LU91556I2 (fr) 1991-04-25 2009-04-24 Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB

Country Status (16)

Country Link
US (3) US5795965A (fr)
EP (1) EP0628639B1 (fr)
JP (6) JP3370324B2 (fr)
KR (1) KR100249937B1 (fr)
AT (1) ATE181575T1 (fr)
AU (2) AU668349B2 (fr)
DE (2) DE122009000019I1 (fr)
DK (1) DK0628639T3 (fr)
ES (1) ES2134212T3 (fr)
GR (1) GR3031174T3 (fr)
HU (1) HU218140B (fr)
LU (1) LU91556I2 (fr)
NL (1) NL300383I2 (fr)
RU (1) RU2139351C1 (fr)
TW (1) TW205553B (fr)
WO (1) WO1992019759A1 (fr)

Families Citing this family (325)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
TW458985B (en) * 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
KR100304333B1 (ko) * 1993-08-24 2001-11-30 안도 고끼 재조합의사람화된항-사람면역결핍바이러스항체
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
AU7949394A (en) 1993-11-19 1995-06-06 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
WO1995029690A1 (fr) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Peptides biologiquement actifs et procedes permettant leur identification
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
ATE552012T1 (de) 1994-10-07 2012-04-15 Chugai Pharmaceutical Co Ltd Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
CZ298325B6 (cs) * 1994-10-21 2007-08-29 Kishimoto@Tadamitsu Farmaceutický prípravek pro prevenci nebo lécení plasmocytosy
WO1996025174A1 (fr) * 1995-02-13 1996-08-22 Chugai Seiyaku Kabushiki Kaisha Inhibiteur de decomposition des proteines musculaires contenant un anticorps du recepteur de l'interleukine-6
AU3276297A (en) 1996-06-27 1998-01-14 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
CN100335501C (zh) 1996-09-26 2007-09-05 中外制药株式会社 抗人副甲状腺激素相关蛋白的抗体
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
ATE297219T1 (de) 1997-02-12 2005-06-15 Chugai Pharmaceutical Co Ltd Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
ATE547119T1 (de) 1997-03-21 2012-03-15 Chugai Pharmaceutical Co Ltd Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen
SK155799A3 (en) 1997-05-15 2000-06-12 Chugai Pharmaceutical Co Ltd Cachexia remedy
ATE395933T1 (de) * 1997-08-15 2008-06-15 Chugai Pharmaceutical Co Ltd Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
DK1074268T3 (da) 1998-03-17 2008-04-28 Chugai Pharmaceutical Co Ltd IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
PL343322A1 (en) 1998-04-03 2001-08-13 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
PT1108435E (pt) * 1998-08-24 2007-04-30 Chugai Pharmaceutical Co Ltd Agentes preventivos ou terapêuticos para pancreatite contendo antagonistas da il-6 como ingrediente activo
PT2261335T (pt) 1998-11-27 2017-09-08 Ucb Pharma Sa Composições e métodos para aumentar a mineralização óssea
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
WO2001016166A2 (fr) * 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides comprenant des domaines de recepteur d'interleukine-6 se liant a un ligand, acides nucleiques correspondants, anticorps, compositions, et leurs procedes d'utilisation
EP1222854B1 (fr) 1999-10-01 2011-02-16 Chugai Seiyaku Kabushiki Kaisha Prevention et traitement de maladies associees a la coagulation sanguine
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
EP1283057B2 (fr) 2000-04-28 2012-05-30 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de proliferation cellulaire
EP2311492B1 (fr) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Préparations stabilisées contentant und anticorps
WO2002032374A2 (fr) * 2000-10-18 2002-04-25 Immunex Corporation Methodes de traitement de troubles induits par l'il-18
AU1091802A (en) 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded agonist antibody
CN1308447C (zh) 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
JPWO2002033072A1 (ja) 2000-10-20 2004-02-26 中外製薬株式会社 低分子化ｔｐｏアゴニスト抗体
US7320792B2 (en) 2000-10-25 2008-01-22 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
WO2002036165A1 (fr) * 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
AU2000279624A1 (en) * 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
AU2002322478A1 (en) * 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
ES2869895T3 (es) 2001-03-09 2021-10-26 Chugai Pharmaceutical Co Ltd Método de purificación de proteínas
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1382964A4 (fr) 2001-04-17 2009-06-10 Chugai Pharmaceutical Co Ltd Procede de quantification de tensioactif
ATE446317T1 (de) * 2001-05-11 2009-11-15 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
AU2003211990A1 (en) * 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
WO2004022597A1 (fr) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Anticorps d'un peptide n-terminal du gpc3 solubilise dans le sang
WO2003090779A1 (fr) * 2002-04-25 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Remede contre le cancer du poumon
EP1513879B1 (fr) * 2002-06-03 2018-08-22 Genentech, Inc. Bibliotheques de phages et anticorps synthetiques
WO2004019966A1 (fr) 2002-08-27 2004-03-11 Chugai Seiyaku Kabushiki Kaisha Methode de stabilisation de preparations de solution de proteines
EP2261230B1 (fr) 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Méthode de purification d'une protéine
PL378199A1 (pl) * 2003-02-24 2006-03-06 Chugai Seiyaku Kabushiki Kaisha Środek terapeutyczny do stosowania w urazach rdzenia kręgowego, zawierający antagonistę interleukiny-6
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
MEP2808A (xx) 2003-06-16 2010-02-10 Celltech R & D Inc Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju
AU2004256354B2 (en) 2003-07-15 2011-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
DK1690550T3 (da) 2003-10-17 2012-11-05 Chugai Pharmaceutical Co Ltd Terapeutisk middel til mesothelioma
CN1914320A (zh) * 2003-12-03 2007-02-14 中外制药株式会社 利用哺乳类β肌动蛋白启动子的表达体系
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
WO2005080429A2 (fr) * 2004-02-11 2005-09-01 Warner-Lambert Company Llc Methodes de traitement de l'osteoarthrose avec des antagonistes de l'interleukine-6
EP1720908A2 (fr) * 2004-02-17 2006-11-15 Absalus, Inc. Anticorps super-humanises contre les virus respiratoires syncytiaux
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP3269738A1 (fr) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Sous-types d'anticorps humanisés contre le récepteur de l'interleukine-6
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
WO2006046661A1 (fr) * 2004-10-28 2006-05-04 Osaka University Agent inhibiteur de l’interleucine-6
JP4818936B2 (ja) 2005-01-05 2011-11-16 中外製薬株式会社 細胞の培養方法およびその利用
DK1859793T3 (da) * 2005-02-28 2011-08-01 Eisai R&D Man Co Ltd Hidtil ukendt kombinationsanvendelse af en sulfonamidforbindelse i behandlingen af cancer
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
WO2006106905A1 (fr) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d’un ensemble
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US9074189B2 (en) 2005-06-08 2015-07-07 Janssen Biotech, Inc. Cellular therapy for ocular degeneration
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CA2610987C (fr) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilisant pour une preparation de proteine contenant de la meglumine et son utilisation
EP2594591B1 (fr) * 2005-08-11 2018-06-06 Arpi Matossian-Rogers Peptides associés au tcr-v beta pour traitement et diagnostic d'une maladie auto-immune
RU2446826C2 (ru) * 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
EP2465870A1 (fr) 2005-11-07 2012-06-20 Genentech, Inc. Polypeptides de liaison dotés de séquences hypvervariables VH/VL diversifiées et consensuelles
JP5398987B2 (ja) 2005-11-14 2014-01-29 セルミド リミテッド 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AR057941A1 (es) 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
WO2007074880A1 (fr) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha Préparation stabilisatrice contenant des anticorps
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
EP1997505A4 (fr) 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd Préparation de solution d'érythropoïétine
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CA2648644C (fr) 2006-04-07 2016-01-05 Osaka University Promoteur de regeneration musculaire
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
EA017303B1 (ru) * 2006-05-25 2012-11-30 Глаксо Груп Лимитед Модифицированные гуманизированные антитела против интерлейкина-18 и их применение
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
ES2405618T3 (es) 2006-06-21 2013-05-31 Oncotherapy Science, Inc. Anticuerpos monoclonales dirigidos a tumores para FZD10 y usos de los mismos
CA2666599A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
WO2008042611A2 (fr) * 2006-09-29 2008-04-10 Centocor, Inc. Procédé permettant d'utiliser des antagonistes il-6 avec la mitoxantrone pour traiter le cancer de la prostate
RU2450829C2 (ru) 2007-01-23 2012-05-20 Синсу Юниверсити Ингибитор хронического отторжения
CA2676008A1 (fr) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions et procedes utilises pour le diagnostic et le traitement du cancer
JP5276017B2 (ja) 2007-01-25 2013-08-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ変異体仲介性疾患の治療における抗ｅｇｆｒ抗体の使用
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
CA2688829A1 (fr) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Nouvelles methodes d'humanisation d'anticorps de lapin et anticorps humanises de lapin
SI2164514T1 (sl) * 2007-05-21 2017-04-26 Alderbio Holdings Llc Protitelesa proti IL-6 in njihova uporaba
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8178101B2 (en) * 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
JP5142265B2 (ja) * 2007-05-28 2013-02-13 独立行政法人産業技術総合研究所 抗モータリン抗体のパラトープ及びエピトープ
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
EP2174667B1 (fr) 2007-07-26 2017-01-04 Osaka University Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
KR101617243B1 (ko) 2007-07-31 2016-05-02 라이프스캔, 인코포레이티드 인간 배아 줄기 세포의 분화
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
MY163473A (en) 2007-09-26 2017-09-15 Chugai Pharmaceutical Co Ltd Modified antibody constant region
EP2206775B1 (fr) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anticorps du récepteur anti-il-6
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
KR101601986B1 (ko) 2007-10-02 2016-03-17 추가이 세이야쿠 가부시키가이샤 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
JP4976502B2 (ja) † 2007-10-15 2012-07-18 中外製薬株式会社 抗体の製造方法
US9062290B2 (en) 2007-11-27 2015-06-23 Lifescan, Inc. Differentiation of human embryonic stem cells
DK2236604T3 (en) 2007-12-05 2016-10-03 Chugai Pharmaceutical Co Ltd The anti-NR10 antibody and use thereof
WO2009075344A1 (fr) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center Agent thérapeutique pour une leucémie mll et une leucémie moz dont la cible moléculaire est le récepteur m-csf, et son utilisation
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009095489A2 (fr) * 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
AU2009215516B2 (en) 2008-02-21 2014-12-18 Janssen Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
CN107488228A (zh) 2008-04-11 2017-12-19 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US9029508B2 (en) * 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2724279C (fr) 2008-05-13 2017-03-07 Novimmune S.A. Anticorps anti-il-6/il-6r et procedes d'utilisation
EP3002299A1 (fr) 2008-06-03 2016-04-06 AbbVie Inc. Immunoglobulines à deux domaines variables et leurs utilisations
CN102112494A (zh) 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
CN102256623A (zh) 2008-06-05 2011-11-23 独立行政法人国立癌症研究中心 神经浸润抑制剂
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
BRPI0914116A2 (pt) 2008-06-30 2019-09-17 Centocor Ortho Biotech Inc diferenciação de células-tronco pluripotentes
NZ590131A (en) 2008-07-08 2012-10-26 Oncomed Pharm Inc Notch-binding agents and antagonists and methods of use thereof
JP5674654B2 (ja) 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US9012218B2 (en) 2008-10-31 2015-04-21 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
JP5785088B2 (ja) 2008-10-31 2015-09-24 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の膵内分泌系への分化
EP2366021B1 (fr) 2008-11-20 2017-08-02 Janssen Biotech, Inc. Culture de cellules souches pluripotentes sur des micro-supports
CN102257132B (zh) 2008-11-20 2014-09-03 森托科尔奥索生物科技公司 用于在平面基底上进行细胞附着和培养的方法和组合物
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
WO2010107110A1 (fr) 2009-03-19 2010-09-23 中外製薬株式会社 Variant d'une région constante d'anticorps
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
US10618964B2 (en) 2009-04-10 2020-04-14 Ablynx N.V. Nanobody against IL-6R
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
AU2010242840B2 (en) * 2009-05-01 2014-04-17 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
AU2010276438B2 (en) 2009-07-20 2015-06-11 Janssen Biotech Inc. Differentiation of human embryonic stem cells
TWI523661B (zh) * 2009-07-31 2016-03-01 Shin Maeda Anti-IL-6 receptor antibody in the manufacture of inhibitors of metastatic inhibition of lung cancer metastasis to the liver
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
KR20140015139A (ko) * 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
BR122022001178B1 (pt) 2009-10-26 2022-10-04 F. Hoffmann-La Roche Ag Método para a produção de uma imunoglobulina glicosilada e seu uso
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011066378A2 (fr) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonistes de l'il-6 destinés à prévenir ou à traiter la thrombose
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
PL2516626T3 (pl) 2009-12-23 2017-10-31 Janssen Biotech Inc Różnicowanie ludzkich zarodkowych komórek macierzystych
RU2701335C2 (ru) 2009-12-23 2019-09-25 Янссен Байотек, Инк. Способ получения популяции панкреатических эндокринных клеток, соэкспрессирующих nkx6.1 и инсулин, и способ лечения диабета
EP2519542B1 (fr) 2009-12-28 2018-10-10 OncoTherapy Science, Inc. Anticorps anti-cdh3 et utilisations de ceux-ci
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2011088215A2 (fr) * 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Agents de liaison notch1 et leurs procédés d'utilisation
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
JP6013196B2 (ja) 2010-03-01 2016-10-25 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞から誘導した細胞を精製するための方法
WO2011108638A1 (fr) 2010-03-04 2011-09-09 大日本住友製薬株式会社 Médicament pour une maladie intestinale inflammatoire
EP2543730B1 (fr) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante de région constante d'anticorps
WO2011128096A1 (fr) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Marqueurs de polymorphisme destinés à prédire la réponse à un traitement par un médicament anticorps monoclonal inhibant les récepteurs de l'interleukine-6
CA2800610C (fr) 2010-05-12 2019-09-24 Janssen Biotech, Inc. Differentiation de cellules souches embryonnaires humaines
EP3195880B1 (fr) 2010-05-14 2019-11-27 Amgen Inc. Formulations d'anticorps anti-sclerostin hautement concentree
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
PL2578231T3 (pl) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
CN103025354A (zh) 2010-06-02 2013-04-03 大日本住友制药株式会社 自身免疫疾病和变应性疾病的治疗药
JP2013529089A (ja) 2010-06-07 2013-07-18 エフ．ホフマン−ラ ロシュ アーゲー インターロイキン−６受容体を阻害するモノクローナル抗体による薬剤治療に対する応答を予測するための遺伝子発現マーカー
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
WO2012019168A2 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucléiques modifiés et leurs procédés d'utilisation
BR112013004581A2 (pt) 2010-08-26 2017-06-27 Abbvie Inc imunoglobulinas de domínio variável dual e seus usos
SG10201506855RA (en) 2010-08-31 2015-10-29 Janssen Biotech Inc Differentiation of human embryonic stem cells
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
JP5828902B2 (ja) 2010-10-29 2015-12-09 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
BR112013010544A2 (pt) * 2010-10-29 2016-08-02 Immunogen Inc moléculas de ligação ao egfr e imunoconjugados das mesmas
WO2012064627A2 (fr) 2010-11-08 2012-05-18 Genentech, Inc. Anticorps anti-récepteur de l'il-6 administré par voie sous-cutanée
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
CA2818813C (fr) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anticorps anti-il-6 utilises pour le traitement de la stomatite
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
KR20230005405A (ko) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
JP2014511842A (ja) 2011-03-25 2014-05-19 アムジエン・インコーポレーテツド 抗スクレロスチン抗体結晶およびその製剤
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
WO2012167346A1 (fr) 2011-06-10 2012-12-13 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Anticorps antiricine et leurs utilisations
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
JP2014523900A (ja) 2011-06-28 2014-09-18 インヒブルクス リミティド ライアビリティ カンパニー セルピン融合ポリペプチド及びその使用方法
WO2013012022A1 (fr) 2011-07-19 2013-01-24 中外製薬株式会社 Préparation à teneur en protéines stable renfermant de l'argininamide ou un composé analogue correspondant
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
WO2013017656A1 (fr) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonistes de ribonucléases pour traiter l'obésité
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
WO2013017691A1 (fr) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Inhibiteurs de cahgtlp destinés à être utilisés dans le traitement de la candidiase
BR112014004828B8 (pt) 2011-09-01 2022-03-29 Chugai Pharmaceutical Co Ltd Métodos para preparação de composições compreendendo anticorpos ou proteínas concentradas por ultrafiltração
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
DE102011083811A1 (de) * 2011-09-30 2013-04-04 Airbus Operations Gmbh Sitzvorrichtung für ein Luft- oder Raumfahrzeug
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2013059548A1 (fr) 2011-10-19 2013-04-25 Sanofi Compositions et méthodes de traitement du cancer à l'aide d'un inhibiteur de jak2
CN109022465B (zh) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
JO3370B1 (ar) 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
RU2014121820A (ru) 2011-11-21 2015-12-27 Иммьюноджен, Инк. Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством
EP2785731B1 (fr) * 2011-11-30 2019-02-20 AbbVie Biotechnology Ltd Vecteurs et cellules hôtes comportant un promoteur sv40 modifié pour expression de protéine
JP2015501654A (ja) * 2011-12-13 2015-01-19 ノルディック ナノベクター アーエス 治療用キメラ型抗ｃｄ３７抗体ｈｈ１
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
SG10201608914WA (en) 2011-12-22 2016-12-29 Janssen Biotech Inc Differentiation of human embryonic stem cells into single hormonal insulin positive cells
AU2012362898B2 (en) 2011-12-28 2017-11-09 Amgen, Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
CA2867299C (fr) 2012-03-15 2019-08-27 John Chen Anticorps anti-cd27 humains, leurs procedes et leurs utilisations
EP2834259A4 (fr) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Polynucléotides modifiés
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013156443A1 (fr) 2012-04-17 2013-10-24 F. Hoffmann-La Roche Ag Procédé d'expression de polypeptides faisant appel à des acides nucléiques modifiés
KR101510831B1 (ko) * 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제
KR101510302B1 (ko) * 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 Ｉｌ-６ 수용체를 표적으로 하는 항체가 생성되도록 미니서클 벡터를 통해 형질전환된 줄기세포 치료제
KR101510830B1 (ko) 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 생리활성 단백질을 발현하는 미니서클을 이용하여 형질전환된 줄기세포를 통한 치료법
BR112014030682A2 (pt) 2012-06-08 2017-06-27 Janssen Biotech Inc diferenciação de células tronco embrionárias humanas em células pancreáticas endócrinas
CN104619342A (zh) 2012-07-05 2015-05-13 Ucb医药有限公司 骨疾病的治疗
JP6282591B2 (ja) 2012-09-13 2018-02-21 中外製薬株式会社 遺伝子ノックイン非ヒト動物
WO2014052462A2 (fr) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Anticorps activables qui se lient au récepteur d'interleukine-6 et procédés d'utilisation de ces derniers
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CA2892529C (fr) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Arn modifie a son extremite terminale
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
RU2684215C2 (ru) 2012-12-31 2019-04-04 Янссен Байотек, Инк. Способ получения панкреатических эндокринных клеток (варианты) и способ увеличения выхода бета-клеток
JP6557146B2 (ja) 2012-12-31 2019-08-07 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞から膵臓内分泌細胞膵臓内分泌細胞への分化のための、空気−液体界面での、ヒト胚性幹細胞の培養
SG11201505119UA (en) 2012-12-31 2015-07-30 Janssen Biotech Inc Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
MX363403B (es) 2013-07-04 2019-03-22 Hoffmann La Roche Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero.
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
CA2926218A1 (fr) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides codant pour un recepteur de lipoproteines de faible densite
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
BR112016013347B1 (pt) 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
BR112016014824A2 (pt) 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
EP2898896A1 (fr) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents pour utilisation dans le traitement de l'inflammation de la rétine
WO2015116852A1 (fr) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de la polyarthrite rhumatoïde par l'administration d'un anticorps anti il-6r
UY36041A (es) 2014-03-21 2015-09-30 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
MX2016015004A (es) 2014-05-16 2017-06-27 Janssen Biotech Inc Uso de moleculas pequeñas para mejorar la expresion de mafa en celulas endocrinas pancreaticas.
WO2016027859A1 (fr) 2014-08-20 2016-02-25 中外製薬株式会社 Procédé de mesure de viscosité de solution de protéine
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016062766A1 (fr) 2014-10-21 2016-04-28 Ablynx Nv Traitement de maladies associées à il-6r
CA2965414C (fr) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Variantes de l'interferon .alpha.2.beta.
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
CA2971186A1 (fr) 2014-12-15 2016-06-23 The Regents Of The University Of California Molecules cytotoxiques reagissant a des ligands intracellulaires pour la destruction selective mediee par les lymphocytes t
WO2016098356A1 (fr) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-c5 et leurs procédés d'utilisation
EP3240804A4 (fr) 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
EP3816179A3 (fr) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Variant de région fc comprenant un domaine de liaison fcrn modifié
KR20180095740A (ko) 2015-02-27 2018-08-27 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
AR104050A1 (es) 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
WO2016159213A1 (fr) 2015-04-01 2016-10-06 中外製薬株式会社 Procédé pour la production d'un hétéro-oligomère polypeptidique
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
EP3371224A1 (fr) 2015-11-03 2018-09-12 Sanofi Biotechnology Compositions comprenant des anticorps il6r pour le traitement de l'uvéite et l'oedème maculaire et leurs procédés d'utilisation
EP3394098A4 (fr) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
EP3398965A4 (fr) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour favoriser l'efficacité de purification d'un polypeptide contenant une région fc
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3431102A4 (fr) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha Médicament thérapeutique induisant des lésions cellulaires à utiliser dans le traitement du cancer
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
CN109963590B (zh) 2016-09-02 2024-03-15 加利福尼亚大学董事会 涉及白介素-6受体α结合单链可变片段的方法和组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
MA46334A (fr) 2016-09-27 2019-08-07 Fresenius Kabi Deutschland Gmbh Composition pharmaceutique liquide
KR102051177B1 (ko) * 2016-10-19 2019-12-17 주식회사 엘지화학 전압 분배를 이용한 스위치 진단 장치 및 방법
AU2017351805A1 (en) 2016-10-31 2019-04-11 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
WO2018156180A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
CN110603057A (zh) 2017-03-17 2019-12-20 俄亥俄州创新基金会 用于递送化学预防剂的纳米颗粒
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
CN107098969B (zh) * 2017-06-28 2018-10-12 武汉波睿达生物科技有限公司 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
TWI825025B (zh) 2017-08-31 2023-12-11 日商田邊三菱製藥股份有限公司 包含il-33拮抗劑的子宮內膜異位症治療劑
US20200369774A1 (en) 2017-09-13 2020-11-26 Jiangsu Hengrui Medicine Co., Ltd. Il-6r antibody and antigen binding fragment thereof and medical use
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
EP3747469A4 (fr) 2018-01-31 2022-03-23 Motokazu Kato Agent thérapeutique pour l'asthme contenant un inhibiteur d'il-6
WO2019177543A1 (fr) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anticorps dirigés contre le virus de la dengue présentant une réactivité croisée au virus zika et procédés d'utilisation
US11466079B2 (en) 2018-03-30 2022-10-11 Amgen Inc. C-terminal antibody variants
JPWO2019225568A1 (ja) 2018-05-21 2021-07-01 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
EP3805112A4 (fr) 2018-05-28 2022-03-09 Chugai Seiyaku Kabushiki Kaisha Buse de remplissage
CA3110891A1 (fr) 2018-08-29 2020-03-05 Regeneron Pharmaceuticals, Inc. Methodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoide
CA3128212A1 (fr) 2019-01-31 2020-08-06 Sanofi Biotechnology Anticorps anti-recepteur de l'il6 pour traiter l'arthrite idiopathique juvenile
KR20210144795A (ko) 2019-03-29 2021-11-30 추가이 세이야쿠 가부시키가이샤 항il-6 수용체 항체를 함유하는 bbb 기능 저하의 억제제
EP3947737A2 (fr) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes
KR20210149779A (ko) 2019-04-10 2021-12-09 추가이 세이야쿠 가부시키가이샤 Fc 영역 개변 항체의 정제 방법
JPWO2020213665A1 (fr) 2019-04-17 2020-10-22
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
CN110483640B (zh) * 2019-07-16 2020-05-01 北京汇智和源生物技术有限公司 白介素-6r的人源化单克隆抗体、其编码基因及应用
CA3170415A1 (fr) 2020-03-03 2021-09-10 Anna M. Ericsson Composes ciblant des proteines de liaison a l'arn ou des proteines modifiant l'arn
EP4107186A1 (fr) 2020-03-23 2022-12-28 Genentech, Inc. Polythérapie à base de tocilizumab et de remdesivir pour une pneumonie à covid-19
WO2021194865A1 (fr) 2020-03-23 2021-09-30 Genentech, Inc. Méthode de traitement d'une pneumonie, y compris la pneumonie à covid-19, avec un antagoniste de l'il6
JP2023518814A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
WO2021211006A1 (fr) 2020-04-13 2021-10-21 Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency Hexapeptide inhalé destiné au traitement de maladies respiratoires liées à l'interleukine-6
EP4149421A1 (fr) 2020-05-15 2023-03-22 F. Hoffmann-La Roche AG Prévention de la formation de particules visibles dans des solutions de protéines parentérales
WO2022005321A1 (fr) 2020-06-29 2022-01-06 Federal State Budgetary Institution Scientific center of biomedical technologies of Federal Medical and Biological Agency Tocilizumab inhalé pour traiter des maladies respiratoires liées à l'interleukine-6
KR20220028972A (ko) 2020-08-31 2022-03-08 (주)셀트리온 안정한 약제학적 제제
US20230357418A1 (en) 2020-09-17 2023-11-09 Genentech, Inc. Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022165419A1 (fr) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Méthodes pour augmenter la fonction des lymphocytes t
EP4306127A1 (fr) 2021-03-12 2024-01-17 Chugai Seiyaku Kabushiki Kaisha Composition pharmaceutique pour le traitement ou la prévention de la myasthénie grave
TW202317622A (zh) 2021-06-11 2023-05-01 美商建南德克公司 以ｓｔ２拮抗劑治療慢性阻塞性肺病的方法
TW202333781A (zh) 2021-10-08 2023-09-01 日商中外製藥股份有限公司 抗ｈｌａ－ｄｑ２﹒５抗體製劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304583A (en) * 1980-06-02 1981-12-08 Corning Glass Works Process for drying optical waveguide preforms
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5082782A (en) 1988-12-27 1992-01-21 Worcester Polytechnic Institute Production of horseshoe crab amebocytes in vitro
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
SG42954A1 (en) * 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies

Also Published As

Publication number Publication date
EP0628639A4 (en) 1994-12-28
JP2000116391A (ja) 2000-04-25
JP3913965B2 (ja) 2007-05-09
DE69229482T2 (de) 1999-11-18
US7479543B2 (en) 2009-01-20
AU1674092A (en) 1992-12-21
WO1992019759A1 (fr) 1992-11-12
HUT70258A (en) 1995-09-28
DE69229482D1 (de) 1999-07-29
HU9303002D0 (en) 1994-01-28
EP0628639A1 (fr) 1994-12-14
KR100249937B1 (ko) 2000-04-01
JP3176598B2 (ja) 2001-06-18
GR3031174T3 (en) 1999-12-31
NL300383I1 (nl) 2009-06-02
RU2139351C1 (ru) 1999-10-10
JP2008073049A (ja) 2008-04-03
JP2004045433A (ja) 2004-02-12
DE122009000019I1 (de) 2009-07-16
ATE181575T1 (de) 1999-07-15
JP3616087B2 (ja) 2005-02-02
JP2001083151A (ja) 2001-03-30
US5817790A (en) 1998-10-06
HU218140B (hu) 2000-06-28
JP2007082560A (ja) 2007-04-05
NL300383I2 (nl) 2010-02-01
AU668349B2 (en) 1996-05-02
TW205553B (fr) 1993-05-11
AU692100B2 (en) 1998-05-28
DK0628639T3 (da) 2000-01-24
JP3370324B2 (ja) 2003-01-27
EP0628639B1 (fr) 1999-06-23
AU5621396A (en) 1996-10-24
US20050142635A1 (en) 2005-06-30
ES2134212T3 (es) 1999-10-01
US5795965A (en) 1998-08-18

Similar Documents

Publication Publication Date Title
LU91556I2 (fr) Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB
DK0669836T3 (da) Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
HK1109633A1 (en) Chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen
NO991591L (no) Rekonstituert human anti-HM1.24 antistoff
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
BR9812846A (pt) Anticorpo humanizado natural
EP0444856A3 (en) Diagnostic assay for alzheimer's disease
DE69528624D1 (de) Anti-Fas Antikörper gegen rheumatische Krankheiten
PT88157A (pt) Antigenes d'excretion-secretion specifiques de toxoplasma gondii leurs produits d'expression leurs procedes d'obtention et leurs applications diagnostiques et prophylactiques
ES2000615A6 (es) Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"
DK102589A (da) Antigen, der genkendes af mca 16-88
EP0537168A4 (en) Ctaa 28a32, the antigen recognized by mca 28a32
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
Ishii et al. Methods of oral examination basis and application of dental health surveys by WHO (4)
IT8204983V0 (it) Dispositivo per la regolazione dell'altezza e dell'inclinazione del sedile di una poltrona anatomica